FLEM could go up a lot. FLEM will make all its money off
collaborative agreements with major pharmaceutical
companies based on its products. It already has 2 products
with patent-pending and 2 development agreements with major
pharmaceutical companies inked.
The latest 10Q shows enough cash to go 24 months. That means
investors will be fighting over the existing tiny float
for 2 years with no dilution as the licensing agreements
pour in- FLEM is looking at 50 drugs it can license
its patent-pending drug delivery process. SLHO signed just 1 licencing agreement with
Texaco based on their patented system and the stock went
from $5-$70 last year. RNTK looks like it will do the
same this year.
So there are big possibilities in licensing agreements for FLEM- you can
reap the rewards of 15 years of hard work and STEAL
it at $1.62- just 20% what people paid 1 month ago.
FLEM is a sucessful
consulting company thats been open since 1982.
The principals are PHD's and nobody's paid less than $5
for the stock except for the MOPA related crash.
All FLEM does is license their product and get checks
in the mail- they don't have to go through the cost and
expense of the manufacturing process-its all profit.
Thats why at $1.62 its a STEAL... people might be fighting over
this stock at $20, $30, or $60 this year if even
1 licensing agreement is announced.
Along with VCLL with their special paints and ISON
with their monopoly of depleted zinc writing
long-term sales contracts with all the nuclear power
plants worldwide, FLEM licencing its 2 medical
devices will reap exponential returns from the MOPA
crash. And since all 3 stocks have tiny floats, the
returns will be quick.
From EDGAR filings:
Company Background
Flemington Pharmaceutical Corporation, a New Jersey corporation (the
"Company"), is engaged in the development of novel application drug delivery
systems for presently marketed prescription and over-the-counter ("OTC")
drugs. The Company's patent-pending delivery systems are lingual sprays and
soft gelatin bite capsules, enabling drug absorption through the oral mucosa,
and more rapid absorption into the bloodstream than presently available oral
delivery systems. The Company's proprietary oral dosage delivery systems
enhance and greatly accelerate the onset of the therapeutic benefits which the
drugs are intended to produce. The Company refers to its delivery systems as
Immediate-Immediate Release I(2)R(TM) because its delivery systems are designed
to provide therapeutic benefits within minutes of administration. The
Company's development efforts for its novel drug delivery systems are
concentrated on drugs which are already available and proven in the
marketplace. In addition to increasing bioavailability by avoiding metabolism
by the liver before entry into the bloodstream, the Company believes that its
proprietary delivery systems offer the following significant advantages:
4
(i) improved drug safety profile by reducing the required dosage, including
possible reduction of side-effects; (ii) improved dosage reliability; (iii)
allowing medication to be taken without water; and (iv) improved patient
convenience and compliance.
The Company has initially identified approximately fifty (50)
presently marketed drugs that meet the Company's criteria for its drug
delivery systems. The Company will concentrate its product development
activities on those pharmaceuticals with significant prescription or OTC
sales. The Company believes that applying a novel application delivery system
to existing drugs involves less cost, time and risk than developing and
commercializing a new chemical entity. The Company believes that there is
significant opportunity to combine its delivery systems with existing
pharmaceuticals to expand the market for an existing drug, differentiate a
product from a generic or brand name competition, and possibly create new
markets. In light of the material expense and delays associated with
independently developing and obtaining approval of pharmaceutical products,
the Company will only continue to develop such products through collaborative
arrangements with major pharmaceutical companies, which will fund that
development. To date, the Company has signed two such development agreements
with major pharmaceutical companies.
The Company was incorporated in New Jersey in 1982 under the name
Pharmaconsult, Inc. and in 1992 the Company's name was changed to Flemington
Pharmaceutical Corporation. Since its inception, the Company has been a
consultant to the pharmaceutical industry, focusing on product development
activities of various European pharmaceutical companies, and since 1992 has
used its consulting revenues to fund its own product development activities.
The Company's recent focus on developing its own products evolved naturally
out of its consulting experience for other pharmaceutical companies.
Substantially all of the Company's revenues have been derived from its
consulting activities. The Company's business address is 43 Emery Avenue,
Flemington, New Jersey 08822, and its telephone number is (908) 782-3431. |
